Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients

Autor: Eklöf, J., Sørensen, R., Ingebrigtsen, T.S., Sivapalan, P., Achir, I., Boel, J.B., Bangsborg, J., Ostergaard, C., Dessau, R.B., Jensen, U.S., Browatzki, A., Lapperre, T.S., Janner, J., Weinreich, U.M., Armbruster, K., Wilcke, T., Seersholm, N., Jensen, J.U.S.

Publikováno v: In Clinical Microbiology and Infection February 2020 26(2):227-234

Treatment with methotrexate and risk of lung disease in patients with rheumatoid arthritis:a nationwide population-based cohort study from Denmark

Autor: Helene Ibfelt, E., Kart Jacobsen, R., Kopp, T. I., Cordtz, R., Svarre Jakobsen, A., Seersholm, N., Burhan Shaker, S., Dreyer, L.

Publikováno v: Helene Ibfelt, E, Kart Jacobsen, R, Kopp, T I, Cordtz, R, Svarre Jakobsen, A, Seersholm, N, Burhan Shaker, S & Dreyer, L 2020, ' Treatment with methotrexate and risk of lung disease in patients with rheumatoid arthritis : a nationwide population-based cohort study from Denmark ', Annals of the Rheumatic Diseases, vol. 79, no. Suppl. 1, OP0232 , pp. 147-148 . https://doi.org/10.1136/annrheumdis-2020-eular.1609

Background: Methotrexate (MTX) is the recommended first-line drug in EULAR and ACR treatment guidelines for rheumatoid arthritis (RA) and hence the most commonly prescribed DMARD in the treatment of this group of patients. However, lung disease is co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c7c7e9b19d643f11c8082aa3bd151c7f
https://vbn.aau.dk/da/publications/4d91b1e8-89ed-4855-b2ce-6da85c78b7b1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial

Autor: Chapman, K.R., Burdon, J.G.W., Piitulainen, E., Sandhaus, R.A., Seersholm, N., Stocks, J.M., Stoel, B.C., Huang, L.P., Yao, Z.L., Edelman, J.M., McElvaney, N.G., RAPID Trial Study Grp

Publikováno v: Lancet, 386(9991), 360-368

Summary Background The efficacy of α1 proteinase inhibitor (A1PI) augmentation treatment for α1 antitrypsin deficiency has not been substantiated by a randomised, placebo-controlled trial. CT-measured lung density is a more sensitive measure of dis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::509c38c1a2f0f3a3d4cf91212de13627
https://doi.org/10.1016/s0140-6736(15)60860-1

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.